Transurethral Incision of Bladder Neck Contracture (TUIBNC)
Transurethral incision is an initial treatment option for nonobliterative bladder-neck stenosis after benign prostate surgery and vesicourethral anastomotic stenosis (VUAS) after radical prostatectomy. These are different anatomical populations; results should not be pooled into one expected success rate. EAU guidance supports transurethral resection or hot-knife incision for bladder-neck stenosis after benign outlet surgery, and visually controlled dilation or DVIU for nonobliterative VUAS.[1]
See BNC, VUAS, and the resection technique.
Selection and operative safety
Confirm the prior operation, radiation exposure, stenosis location and length, residual lumen, baseline continence, and bladder function. Identify fistula, radionecrosis or complete obliteration before attempting treatment. Do not attempt endoluminal treatment of a completely obliterated posterior stenosis. Releasing obstruction can reveal or worsen sphincteric incontinence.[1]
Avoid deep incisions at 6 and 12 o'clock because of rectal injury and urosymphyseal fistula risk, particularly after radiation. Lateral incisions do not eliminate sphincter injury, extravasation or fistula risk. The desired endpoint is controlled opening of the stenosis within the patient's anatomy, not indiscriminate exposure of fat.[1]
Technique
- Assess the lumen cystoscopically and establish safe access under direct vision. Antegrade assessment through a suprapubic tract can help when anatomy is uncertain.
- In the published Nealon/Ramirez protocol, a 24 Fr balloon permits resectoscope access, followed by bilateral 3 and 9 o'clock incisions with an electrocautery Collins knife. The reported technique divides the scar deeply; its depth must be adapted to the location, prior reconstruction and radiation injury. A Collins electrocautery knife is distinct from a cold knife.[2][3]
- Confirm a patent channel, hemostasis and catheter drainage. Catheter size and duration depend on tissue injury, the procedure performed and the drainage plan.
Laser incision is another available method; current posterior-stenosis evidence does not establish one incision energy as universally superior. Transverse mucosal realignment is an evolving reconstructive variant supported by small observational cohorts.[1][4]
Outcomes and their limits
| Study | Population and design | Reported outcome |
|---|---|---|
| Nealon 2022 | Retrospective, 123 patients with heterogeneous BNC/VUAS; balloon plus Collins incisions, no injection | 101/123 (82.1%) patent after one procedure; 116/123 (94.3%) after a second; median follow-up 12 months. Patency assessment included passage of a 16 Fr cystoscope at approximately 2 months.[2] |
| Ramirez 2013 | 50 patients; 78% had prior endoscopic treatment | 72% success after one procedure, 86% after two; mean follow-up 12.9 months.[3] |
| Rosenbaum 2021 | 60 patients after benign prostate surgery; VUAS excluded; 49 resections and 11 incisions | 32/60 (53%) overall success. The small nonrandomized comparison does not establish equivalence of incision and resection.[5] |
| Abramowitz 2021 | 19 patients, one surgeon; incision plus mucosal realignment | 89% success after one procedure and 100% after a repeat procedure; median follow-up 6 months. No new incontinence was reported, but the sample and follow-up cannot establish a negligible risk.[4] |
A 2024 systematic review of 40 studies and 1,452 patients with post-prostatectomy anastomotic stenosis estimated endoscopic success at 72.8% (95% CI 64.4–79.9%); adjustment for publication bias lowered the estimate to 62.9% (53.6–71.4%). Techniques, definitions and follow-up varied. These pooled estimates do not establish superiority of a particular method.[6]
Prior interventions and radiation can reduce the chance of durable patency. The associations reported for previous procedures and smoking in individual cohorts are useful counseling factors, not validated rules that mandate reconstruction after exactly two failures.[2][3][1]
Intralesional adjuncts
Mitomycin C should not be used for posterior stenosis outside a clinical trial under EAU guidance. The TURNS cohort reported serious adverse events in 4/55 patients (7%), including osteitis, bladder-neck necrosis and rectourethral fistula; some required major diversion. Other uncontrolled series have more favorable safety reports, but they do not establish a reliably safe dose or incremental benefit.[1][7]
Triamcinolone has been used with incision or resection in recurrent cases. Zhang's 28-patient series reported 26/28 patent outlets after resection plus intraoperative and serial postoperative injections; 25/28 had adequate voiding, with one patient limited by detrusor underactivity. This uncontrolled result cannot separate the effects of surgery, repeated instrumentation and steroid injection.[8]
The Pang adjunct meta-analysis addressed male urethral strictures across heterogeneous settings; its MMC estimates are not a direct comparison establishing MMC as the best BNC adjunct. Similarly, absence of necrosis in a small steroid series does not prove zero risk.[9]
For drug mechanisms, evidence and safety, use the antimitotic/antifibrotic hub and intralesional corticosteroid hub. The no-injection Nealon series demonstrates that favorable outcomes can occur without an adjunct; cross-series comparisons do not prove that incision depth accounts for most treatment benefit.[2]
Continence and further treatment
Record continence before treatment. In Ramirez's referral cohort, 39/50 already had concomitant SUI; 78% is that cohort's baseline prevalence, not an expected complication rate for all post-prostatectomy patients. Twenty-six subsequently underwent AUS placement at a mean of 2.9 months, with 2 requiring later treatment for recurrent stenosis. This selected cohort does not prescribe a universal safe implantation interval or guarantee long-term device safety.[3]
Establish stable patency before continence surgery and reassess symptoms, storage function and suitability for an AUS. Repeated endoscopic treatment can stabilize selected nonobliterative stenoses. Refractory or obliterative disease warrants reconstructive consultation, with approach chosen by location, tissue quality, radiation, bladder function and the patient's goals. Posterior urethral stents are discouraged by EAU guidance.[1]
References
1. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Disease management in males, sections 6.3.5–6.3.6. Guideline.
2. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.
3. Ramirez D, Zhao LC, Bagrodia A, et al. Deep lateral transurethral incisions for recurrent bladder neck contracture: promising 5-year experience using a standardized approach. Urology. 2013;82(6):1430-5. doi:10.1016/j.urology.2013.08.018.
4. Abramowitz DJ, Balzano FL, Ruel NH, Chan KG, Warner JN. Transurethral incision with transverse mucosal realignment for the management of bladder neck contracture and vesicourethral anastomotic stenosis. Urology. 2021;152:102-108. doi:10.1016/j.urology.2021.02.035.
5. Rosenbaum CM, Vetterlein MW, Fisch M, et al. Contemporary outcomes after transurethral procedures for bladder neck contracture following endoscopic treatment of benign prostatic hyperplasia. J Clin Med. 2021;10(13):2884. doi:10.3390/jcm10132884.
6. Delchet O, et al. Post-prostatectomy anastomotic stenosis: systematic review and meta-analysis of endoscopic treatment. BJU Int. 2024. doi:10.1111/bju.16141.
7. Redshaw JD, Broghammer JA, Smith TG, et al. Intralesional injection of mitomycin C at transurethral incision of bladder neck contracture may offer limited benefit: TURNS Study Group. J Urol. 2015;193(2):587-92. doi:10.1016/j.juro.2014.08.104.
8. Zhang L, Liu S, Wu K, Mu X, Yang L. Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections. World J Urol. 2021;39(2):527-532. doi:10.1007/s00345-020-03224-w.
9. Pang KH, Chapple CR, Chatters R, et al. A systematic review and meta-analysis of adjuncts to minimally invasive treatment of urethral stricture in men. Eur Urol. 2021;80(4):467-479. doi:10.1016/j.eururo.2021.06.022.